Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/232251 
Year of Publication: 
2020
Series/Report no.: 
Research Paper No. 125
Publisher: 
South Centre, Geneva
Abstract: 
Competition law and policy has become an important tool for countries to promote access to pharmaceuticals. How can countries design and enforce competition policies that are suitable to the particularities of developing countries? What are the main anti-competitive tactics in the pharmaceutical sector, and how should they be dealt with? This paper deals with these issues, taking into account the socio-economic relevance of access to health products. It finds that developing countries should apply their competition laws in the pharmaceutical sector more actively, and that there is ample policy space under international law to do so. It provides an overview of the way in which competition policies have been applied in some industrialized and developing countries and explores how such policies can be designed and implemented in the context of developing countries.
Subjects: 
Access to Medicines
Competition Law
Competition Policy
Compulsory Licenses
European Commission
Flexibilities
Health
Industrial Policy
Innovation
Intellectual Property
International Competition Network (ICN)
International Law
Organisation for Economic Co-operation and Development (OECD)
Patent
Pharmaceuticals
Research and Development (R&D)
South-South Cooperation
TRIPS
TRIPS Council
UNHLP on Access to Medicines
United Nations Conference on Trade and Development (UNCTAD)
United Nations Development Programme (UNDP)
Voluntary License
World Health Organization (WHO)
World Intellectual Property Organization (WIPO)
World Trade Organization (WTO)
Document Type: 
Research Report
Appears in Collections:

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.